About MultiVir

About company

MultiVir, Inc., a clinical-stage gene therapy company, engages in developing a pipeline of product candidates for the treatment of various oncological indications. The company’s lead product candidates that has completed Phase 1 clinical trials include Ad-p53, a genetically modified adenovirus designed to deliver the normal p53 tumor suppressor gene, which targets fundamental molecular defects present in various types of cancers; and Ad-IL24, a genetically engineered adenovirus modified to deliver the tumor suppressor gene interleukin-24 that has tumor suppressor activities similar to p53 and certain immunostimulatory properties.